Company intelligence / Profile preview
Allovate Therapeutics
- Ownership
- Private
- Employees
- ~6
- Development stage
- Commercial
Overview
Allovate Therapeutics has developed a novel oral mucosal immunotherapy platform for allergy treatment. Their lead product integrates allergen-specific immunotherapeutic agents into a toothpaste base ("Allerdent"), allowing patients to receive daily allergy immunotherapy during routine tooth brushing. This approach aims to improve convenience and adherence while reducing the risk of adverse reactions compared to traditional injection-based therapies. Clinical investigations are ongoing for both food and respiratory allergies; no pivotal or late-stage clinical results have been published yet
- Therapeutic areas
- Immunology
- Modalities
- ProteinRecombinant proteinDevice (toothpaste-based delivery platform)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Allovate Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allovate Therapeutics.